[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anemia-iron-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anemia-iron-deficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,79,105,117,142,170,197,218,244,269,301],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054206","phase-3-co-administration-of-calcium-and-multiple-micronutrient-supplements-for-maternal-and-newborn-hemoglobin-and-iron-status-100054206",false,"NCT06568315","Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status","Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status: A Randomized Non-inferiority Trial in Burkina Faso and Pakistan","CaMMS","Inclusion Criteria:\n\n* Burkina Faso: married or unmarried pregnant women aged ≥15 years\n* Pakistan: married pregnant women ≥18 years\n* Willing to receive all antenatal care at a study clinic\n* Willing to stop iron folic acid supplementation to receive the study intervention\n* Hb ≥70 g\u002FL\n* 6\\\u003C20 weeks of gestation based on fetal ultrasound\n\nExclusion Criteria:\n\n* Burkina Faso: \\\u003C15 years or unmarried pregnant women \\\u003C18 years without consent from parent \u002F guardian\n* Pakistan: pregnant women \\\u003C18 years.\n* Unwilling to receive antenatal care at a study clinic\n* Unwilling to stop iron folic acid supplementation to receive the study intervention\n* Hemoglobin \\\u003C 70 g\u002FL\n* \\\u003C6 weeks of gestation or ≥20 weeks of gestation\n* Non-viable or extrauterine pregnancy\n* Any contraindications to study supplements",true,"FEMALE","15 Years",{"count":21,"type":22},3200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The World Health Organization (WHO) currently recommends the pregnant women receive iron-containing supplements and, in settings where calcium intake is low, calcium supplements. Supplements are to be taken at two separate times of the day as calcium may interfere with iron absorption. The goal of this clinical trial is to learn whether taking daily calcium supplements and iron-containing multiple micronutrient supplements together, at the same time, has any negative impact on the hemoglobin or iron status of pregnant women or the woman's infants. Participants will be randomly assigned and counseled to either take the supplements together every morning or to take the multiple micronutrient supplement in the morning and the calcium supplement in the evening. Participants will visit the antenatal clinic monthly and be asked to provide a blood sample in early, mid, and late pregnancy. Researchers will also take blood samples from infants at the time of birth.",[28],"Anemia, Iron Deficiency",[30,31,32,33,34],"calcium","iron","supplementation","anemia","pregnancy","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2025-08-25",{"date":43,"type":22},"2026-08",{"name":45,"class":46},"Johns Hopkins Bloomberg School of Public Health","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100578372","reducing-anemia-among-preconception-women-in-nepal-through-a-group-norm-and-micronutrient-supplementation-intervention-100578372","NCT06810440","Reducing Anemia Among Preconception Women in Nepal Through a Group Norm and Micronutrient Supplementation Intervention","Reducing Anemia Among Young Preconception Women in Nepal Through a Group Household Norm and Micronutrient Supplementation Intervention","Sumadhur","Inclusion Criteria:\n\n* the newly married couple having been married in the last four months\n* women being under 25 years old\n* never pregnant and not currently pregnant\n* co-residing with the mother-in-law in a household as defined by sharing meals together.\n* all triad-household members must also be willing to participate\n* husbands must not be planning to migrate in the next 6 months.\n\nExclusion Criteria:\n\n* Over 25, under 18 years old\n* Currently or ever pregnant\n* married more than 4 months before\n* not co-residing\n* not being willing to participate.\n* do not consent to blood-draws\n* women who are severely anemic (hemoglobin \\\u003C 8.0 g\u002FdL) at baseline based on hemoglobin via Hemocue assessment of a fingerprick blood sample at the time of enrollment","18 Years","25 Years",{"count":59,"type":22},2100,[61],"NA","Preconception micronutrient status (including anemia) is a critical determinant of maternal, newborn, and child health that remains undervalued in Nepal. However, providing micronutrient supplements (MMS) alone is not enough. In the Nepali context, the gap between marriage and the first birth is short and newly married women have the lowest household status. Addressing the intersectional barriers to health for newly married women, including inequitable gender norms and women's empowerment, household relationships, nutrition knowledge and practices-is essential for improving maternal and infant outcomes in Nepal. To mitigate the community, household, and individual factors resulting in poor nutrition, the team developed and pilot-tested an educational group intervention (Sumadhur, meaning \"Best Relationship\") for newly married women, husbands, and mothers-in-law triads. Sumadhur aims to provide information on nutrition and women's health, address inequitable gender norms and practices, strengthen household relationships and communication, and improve the household status of newly married women. The pilot study of Sumadhur brought triads of several households together for 16 interrelated sessions over four-months. Findings suggest that participants (N=90) found the intervention to be highly feasible and acceptable and nutritional norms and practices improved.\n\nWe propose to test the effectiveness of Sumadhur on maternal health and nutrition outcomes using a 2-arm cluster RCT (cRCT). The intervention participants will receive the Sumadhur group intervention and will be provided MMS directly at group sessions. In control villages who do not receive the Sumadhur group intervention, we will facilitate access to MMS at primary health centers. We will randomize 70 villages to each arm (with one group per village). Each village has one group of five women (total of 700 women). Newly married women, their husbands and mothers-in-laws (total=2,100), will be followed four times for 18 months post-intervention through surveys, hemoglobin tests and blood draws (women only). The specific aims are to estimate the effectiveness of Sumadhur on women's anemia and micronutrient status, including the cost-benefit of the intervention (Aim 1); explore the impact on intermediate outcomes such as gender norms, household relationships and eating practices and characterize the individual and household-level mechanisms of impact (Aim 2); understand triadic experiences and impact over time of Sumadhur (Aim 3).\n\nAccomplishing these aims will provide evidence for how to improve micronutrient and anemia status among women before they become pregnant-thereby ensuring that women are not deficient in the critical early phases of pregnancy. These findings will also advance the field by testing novel approaches (household and community level behavior and norm change intervention) that, when combined with supplements, may lead to better adherence, uptake, and, ultimately, health outcomes, and have additional longer-term benefits.",[64,65,66,67,68],"Anemia, Iron-Deficiency","Nutritional Deficiencies","Adherence","Norms, Social","Knowledge, Attitudes, Practice","2026-03-24",{"date":71,"type":39},"2026-03-30",{"date":73,"type":39},"2025-10-08",{"date":75,"type":22},"2029-04-01",{"name":77,"class":46},"University of California, San Francisco",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":78},"100383897","phase-4-early-antenatal-support-for-iron-deficiency-anemia-100383897","NCT04278651","Early Antenatal Support for Iron Deficiency Anemia","Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy","EASI-A","Inclusion Criteria:\n\n* Singleton gestation\n* Gestational age \\\u003C24 weeks\n* Baseline Hb ≥9.0 and \\\u003C11.0 with evidence of iron deficiency anemia\n\nIron deficiency anemia diagnosed (at any point in patient history) by:\n\n* Hb\\\u003C11.0\n* Ferritin\\\u003C30 and\u002For total iron saturation \\\u003C20\n\nExclusion Criteria:\n\n* Sickle cell Disease (NOT sickle cell trait)\n* Evidence of acute anemia requiring transfusion or IV iron therapy\n* Major congenital or chromosomal anomaly\n* Previous use of IV iron in this pregnancy\n* Severe cardiac, renal, or liver disease\n* Autoimmune disease (ie Systemic Lupus Erythematosus (SLE)\n* Allergy or contraindication to either study drug\n* History of medication allergy, reaction to IV infusion, or reaction to Feraheme or other IV iron products","65 Years",{"count":89,"type":22},80,[91],"PHASE4","This is a randomized, controlled multi-site trial of iron therapy in pregnancy. The purpose of this research is to see if second trimester initiation of intravenous (IV) iron therapy is better than oral iron therapy for treatment of anemia in pregnancy by improving blood count, quality of life and reducing side effects.",[94,28,95],"Pregnancy Related","Anemia of Pregnancy","2025-11-25",{"date":98,"type":39},"2025-12-02",{"date":100,"type":39},"2021-09-29",{"date":102,"type":22},"2026-12-30",{"name":104,"class":46},"Thomas Jefferson University",{"id":106,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":26,"conditions":109,"keywords":110,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":116,"locationsCount":47},"100559759",{"count":21,"type":22},[25],[28],[30,31,32,33,34],"2025-09-16",{"date":113,"type":39},"2025-09-17",{"date":41,"type":39},{"date":43,"type":22},{"name":45,"class":46},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100605505","iron-deficiency-anemia-in-the-second-and-third-trimester-of-pregnancy-100605505","NCT07163390","Iron Deficiency Anemia in the Second and Third Trimester of Pregnancy","Iron Deficiency Anemia in the Second and Third Trimester of Pregnancy: Evaluation of the Contribution of Sucrosomial Iron Supplementation (Sideral® Folico)","PESO","Inclusion Criteria:\n\n* Pregnant women from 24 to 32 weeks of pregnancy\n* Age ≥18 ys old\n* Hemoglobin between 8.5 and 10.5 g\u002Fdl\n* Ability to sign an informed written consent\n\nExclusion Criteria:\n\n* Patients with preclampsia\n* twin pregnancy\n* chronic diseases\n* drug exposure\n* BMI\\\u003C18 or \\>30\n* malabsorption\n* fetal growth restriction\n* age \\\u003C 18 years\n* haematologic diseases\n* symptomatic anemia (dyspnea, tachycardia)\n* inability to sign an informed written consent","50 Years",{"count":127,"type":22},82,[61],"Iron deficiency is the most frequent cause of anemia during pregnancy and of maternal blood transfusion during the post-partum period. Intravenous administration is the fastest route to correct iron deficiency, bypassing the filter of iron intestinal absorption, the only true mechanism of iron balance regulation in the human body. Intravenous iron administration is suggested in patients who are refractory\u002Fintolerant to oral iron sulfate. This approach is expected to increase of at least 1 gr\u002FdL the level of hemoglobin in 4 weeks. However, the intravenous route of iron administration has some drawbacks; first it is allowed only as in-hospital procedure and requires a resuscitation service, in accordance with the recommendations of the European Medicine Agency. Moreover, it is very expensive and negatively affects patient's perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal route of absorption, appears to be better tolerated and more cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. The hypothesis of the present study is that oral sucrosomial iron can correct iron deficiency anemia during pregnancy comparably to intravenous ferrous sulphate, with less side effects.",[28,131],"Pregnancy Anemia","NOT_YET_RECRUITING","2025-09-01",{"date":135,"type":39},"2025-09-09",{"date":137,"type":22},"2025-09-15",{"date":139,"type":22},"2027-09-15",{"name":141,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":150,"minAge":56,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":78},"100412094","depth-of-maximal-ileal-insertion-during-retrograde-enteroscopy-with-tts-balloon-100412094","NCT04646083","Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon","Depth of Maximal Insertion During Retrograde Enteroscopy Using Colonoscopy With Through-the-scope Balloon Enteroscopy (NaviAid) Compared With Using the Standard Colonoscope Alone","NaviAid2","Inclusion Criteria:\n\n1. Sign Informed Consent Form\n2. Patients age between 18-90 years\n3. Patients in which retrograde enteroscopy is indicated for any of the following:\n\nabnormal video capsule endoscopy non-diagnostic upper and lower endoscopy obscure gastrointestinal bleeding iron deficiency anemia non-diagnostic upper endoscopy and abnormal CT Hemodynamically stable\n\nExclusion Criteria:\n\n1. Inability to sign Informed Consent Form\n2. Pregnancy and breast feeding\n3. Prior colon resection\n4. Patients with known strictures\n5. Patients with altered anatomy\n6. Inadequate bowel preparation.","ALL","90 Years",{"count":153,"type":22},100,"OBSERVATIONAL","Diagnostic modalities for the evaluation of small bowel pathology include video capsule endoscopy (VCE), antegrade and retrograde device-assisted enteroscopy, CT and MR enterography (1). Despite VCE being the first-line evaluation modality, it lacks interventional capability. Deep enteroscopy (DE) allows tissue sampling and other therapeutic interventions with real-time endoscopic assessment. DE is usually performed with specific endoscopes (balloon-assisted device or spiral overtube) making it time consuming and there is limited availability since special instruments and accessories are required.(1,2) The through-the-scope (TTS) balloon system consists of a balloon catheter designed for anchoring in the small bowel, inserted through the instrument channel of a standard colonoscope.(3) The catheter is advanced, the balloon is inflated and anchored in the small intestine and the endoscope slides over the guiding catheter to the inflated balloon. The most common indications for DE are obscure GI bleeding, iron deficiency anemia, abnormal capsule endoscopy and chronic diarrhea. As compared to spiral, single-or double-balloon enteroscopy, TTS (NaviAid, SMART Medical Systems Ltd, Ra'anana, Israel) is a simpler technique, which requires less investment in infrastructure. The balloon catheter is advanced blindly in front of a standard adult colonoscope as it bends around the curves of the small bowel. To prevent perforation\u002Ftrauma the catheter is fitted with a soft silicone tip which easily bends under pressure.\n\nInsertion depth can be calculated during the withdrawal of the enteroscope. The Aim of the study: To compare the depth of maximal ileal insertion between through-the-scope balloon enteroscopy (NaviAid) with enteroscopy using the adult colonoscope (Olympus CF-190) alone, in the same patient, in a prospective cohort at University Medical Center of El Paso, Texas.",[157,28],"Obscure Gastrointestinal Bleeding",[159,160],"retrograde enteroscopy","small bowel bleeding","2025-06-13",{"date":163,"type":39},"2025-06-18",{"date":165,"type":39},"2021-01-14",{"date":167,"type":22},"2025-12-31",{"name":169,"class":46},"Texas Tech University Health Sciences Center, El Paso",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":150,"minAge":56,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":180,"conditions":181,"keywords":187,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":78},"100565050","patient-blood-management-in-patients-scheduled-for-cardiac-surgery-100565050","NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery","Patient Blood Management in Cardiac Surgical Patients: the ICARUS-2 Study","ICARUS-2","Inclusion Criteria:\n\n\\- all adult patients scheduled for elective cardiac surgery\n\nExclusion Criteria:\n\n* pregnancy\n* dyalisis\n* patient's refusal",{"count":179,"type":22},464,"The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.\n\nIn particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.",[182,64,183,184,185,186],"Anemia","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia (IDA)","Cardiac Surgical Patients","Blood Loss, Surgical",[31,33,188,189],"cardiac surgery","patient blood management","2025-02-24",{"date":192,"type":39},"2025-02-26",{"date":190,"type":39},{"date":195,"type":22},"2027-02-28",{"name":141,"class":46},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":17,"sex":150,"minAge":56,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":78},"100527349","heme-and-non-heme-iron-intakes-gut-microbiota-and-influence-on-host-iron-absorption-100527349","NCT06146608","Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption","FeMicrobiome","Inclusion Criteria:\n\n* Healthy adults\n* Age between 18- 40y\n* Non-smoking\n* Not currently taking vitamin, mineral, prebiotic, and probiotic supplements.\n* Females: premenopausal and not pregnant or lactating\n* No preexisting medical complications (such as eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis)\n* Body mass index (BMI) between 18 - 27 kg\u002Fm2.\n\nExclusion Criteria:\n\n* BMI \\\u003C18 or \\> 27 kg\u002Fm2,\n* Age \\\u003C18 y or \\> 40y,\n* Smoking\n* Pregnancy, lactating\n* Have gastrointestinal disorders\u002Fmalabsorption diseases\u002Fhemoglobinopathies\u002Fdietary restrictions\u002Fsteroid use\u002F medication use of medications known to impact iron status, iron utilization or inflammatory status\n* Currently take vitamin, mineral, prebiotic, and probiotic supplements.\n* Recently received antibiotic treatment","40 Years",{"count":206,"type":22},120,"The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.",[28,209],"Iron Overload","2025-02-21",{"date":190,"type":39},{"date":213,"type":39},"2023-01-15",{"date":215,"type":22},"2026-01-14",{"name":217,"class":46},"Cornell University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":87,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":78},"100462651","phase-3-iv-iron-trial-for-anemia-related-to-uterine-bleeding-in-female-patients-presenting-to-the-emergency-department-100462651","NCT05304442","IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department","Intravenous Ferric Derisomaltose for Moderate to Severe Anemia Due to Uterine Bleeding in the Emergency Department: a Randomized Trial","Inclusion Criteria:\n\n* Sub-acute or chronic uterine blood loss;\n* Moderate to Severe Anemia, defined as Hgb less than or equal to 9.0 g\u002Fdl;\n* Iron deficiency: Serum ferritin less than or equal to 30 ng\u002FmL;\n* Eligible for discharge from the ED following treatment;\n* Patient able to return for planned follow-up visits at 3 and 6 weeks;\n* Patient able to be reached by telephone;\n* Willing and able to provide consent for participation.\n\nExclusion Criteria:\n\n* Patient requiring hospitalization for any reason;\n* Pregnant or nursing;\n* Incarcerated\u002FPrisoner;\n* Weight \\\u003C 50 kg;\n* History of hypersensitivity reactions, as specified, known hypersensitivity to any formulation of parenteral iron;\n* History of any anaphylactic allergy;\n* Recent receipt of IV iron, erythropoiesis-stimulating agents;\n* Erythropoiesis-stimulating agent use within 8 weeks prior to ED visit;\n* Parenteral iron within 4 weeks prior to ED visit;\n* Scheduled\u002Fplanned use of parenteral iron or ESA during study period;\n* Receipt of blood transfusion at index visit;\n* Planned elective major surgery during study period;\n* Other current or recent hematologic therapy, as specified;\n* Current or planned use of antithrombotic therapy (antiplatelet agents or anticoagulants) within study period (Non-aspirin NSAIDs are NOT a contraindication);\n* Known bleeding disorder platelets \\\u003C 100,000';\n* Other significant underlying comorbidity, as specified:\n* Active rheumatologic disease, or rheumatologist disease requiring treatment, such as rheumatoid arthritis, systemic lupus erythematosus, or mixed connective tissue disease;\n* Acute heart failure or NYHA II-IV chronic heart failure;\n* Inflammatory bowel disease;\n* Cirrhosis or Decompensated liver disease;\n* Chronic kidney disease, stage III or greater (eGFR \\\u003C 60);\n* Current Systemic Infection (e.g. pneumonia, pelvic inflammatory disease, pyelonephritis). \\*Cystitis or cervicitis is NOT an exclusion\n* Any other medical or surgical condition that in the opinion of the treating physician may result in patient being unsuitable for trial participation",{"count":226,"type":22},40,[25],"The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.",[28,230],"Uterine Bleeding",[232,233,234,230],"IV Iron","Emergency Department","Iron Deficiency Anemia","2024-12-03",{"date":237,"type":39},"2024-12-05",{"date":239,"type":39},"2022-09-15",{"date":241,"type":22},"2025-04",{"name":243,"class":46},"Baylor College of Medicine",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":17,"sex":18,"minAge":252,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100510691","phase-4-iron-deficiency-anemia-ida-and-the-brain-100510691","NCT05929729","Iron Deficiency Anemia (IDA) and the Brain","Neurovascular and Neurocognitive Consequences of Iron Deficiency Anemia","IDA","Inclusion Criteria:\n\n* Observational arm:\n\n  1. Age between 16 and 60 years of age.\n  2. Any ethnicity.\n  3. Female\n  4. Anemic group: hemoglobin ≤10.5 g\u002Fdl or hematocrit \\\u003C32% from finger prick or plethysmography test, or \\\u003C11 g\u002Fdl from venipuncture blood draw\n  5. Control group: hemoglobin \\>13.2 g\u002Fdl or hematocrit \\>39.6%\n* Interventional arm:\n\n  1. Criteria for observational component, plus\n  2. Iron deficiency anemia based upon attending hematologist interpretation of transferrin saturation, ferritin, and other ancillary labs including hs-CRP, MMA, hemoglobin electrophoresis\n\nExclusion Criteria:\n\n* Observational arm:\n\n  1. Diabetes requiring medication.\n  2. Hypertension requiring medication.\n  3. Sleep disordered breathing requiring intervention.\n  4. Body mass index \\>40 (morbid obesity)\n  5. Contraindications to MRI, including pacemaker, severe claustrophobia, pregnancy.\n  6. Known systemic inflammatory disease such as inflammatory bowel disease, systemic lupus erythematosus, or scleroderma.\n  7. Known HIV.\n* Interventional arm:\n\n  1. Criteria for observational component, plus\n  2. Prior reaction to intravenous iron.\n  3. History of multiple drug allergies.\n  4. History of severe asthma, eczema, or atopy.\n  5. Systemic mastocytosis.\n  6. Severe respiratory or cardiac disease.\n  7. Having no access to a physician who can manage the iron deficiency anemia.","16 Years","60 Years",{"count":206,"type":22},[91],"This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects. The main purposes of this study is to phenotype the scope of neurocognitive deficits from iron deficiency anemia (IDA) in adult women, determine derangements in cerebral perfusion, vascular reactivity, functional connectivity, and blood brain barrier permeability in adult-onset IDA and relate them to neurocognitive deficits, as well as determine the reversibility and durability of both the physiologic and neurocognitive derangements by iron replacement therapy. All eligible subjects will be asked to provide informed consent before participating in the study.",[258,182,234,28],"IDA - Iron Deficiency Anemia","2024-10-28",{"date":261,"type":39},"2024-10-30",{"date":263,"type":39},"2023-12-07",{"date":265,"type":22},"2028-09-01",{"name":267,"class":46},"Children's Hospital Los Angeles",4,{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":17,"sex":150,"minAge":56,"maxAge":125,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":78},"100551950","the-impact-of-faba-bean-rich-bread-on-iron-status-postprandial-lipaemia-and-satiety-100551950","NCT06466746","The Impact of Faba Bean Rich Bread on Iron Status, Postprandial Lipaemia and Satiety","The Impact of Faba Bean Rich Bread on Iron Status, Postprandial Lipaemia and Satiety in Adults with Low Iron Stores","RtP","Inclusion Criteria:\n\n* Non-anaemic, males and pre-menopausal females (must have regular periods)\n* Aged 18-50 years old\n* BMI between 19 - 30 kg\u002Fm2\n* Low iron stores (serum ferritin between 13-40 µg\u002FL for females and 30-90 µg\u002FL for males)\n\nExclusion Criteria:\n\n* Food allergies or intolerances to faba beans (favism) or gluten\n* Diagnosed with anaemia (haemoglobin \\\u003C115 g\u002FL for females or \\\u003C130 g\u002FL for males) or haemochromatosis\n* C-reactive protein (\\>3mg\u002FL)\n* Smokers\n* A history of alcohol abuse (\\> 14 units\u002F week)\n* CVD or medical history of MI or stroke in the past 12 months\n* Diabetes (fasting glucose \\>7.0 mmol\u002FL)\n* Kidney, liver, pancreas or intestinal disease, gastrointestinal disorder or use of drugs likely to alter gastrointestinal function\n* Pregnancy, planning a pregnancy in the next six months or breastfeeding\n* Peri- and post-menopausal women or women with irregular periods\n* Planning on a weight-reducing regimen (lost \\>3kg in last 6 months)\n* Parallel participation in another intervention study\n* Hypertension (blood pressure \\> 140\u002F90 mmHg), cancer, taking medication for hyperlipidaemia (statins), or inflammation\n* Taking vitamin or mineral supplements\n* Donated blood in the last 3 months\n* Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (such as a pacemaker)",{"count":278,"type":22},16,[61],"High levels of animal proteins (meat) in the diet are linked with a greater risk of developing heart disease and other long-term health conditions. Recently there has been a shift to plant-based diets including plant proteins such as pulses, defined as beans, peas, chickpeas and lentils. Pulses are a nutritious and sustainable form of plant protein which are rich in fibre and iron. Despite this, the UK population does not consume the recommended daily amount of pulses (80g\u002Fday equivalent to a large handful). In contrast, bread is commonly consumed but very little is known about how bread enriched with pulses influences the amount of iron that is digested and absorbed by the body as well as risk factors for developing heart disease and type 2 diabetes.\n\nThe main purpose of this randomised controlled cross-over study is to determine how consuming bread enriched with pulses (in the form of faba bean flour at approximately 40% enrichment) compared with conventional white bread (100% wheat flour) influences the amount of iron absorbed in healthy males and females aged 18-50 years with low iron stores. Secondary aims are determining the effects on blood fats and sugar (glucose) and on feelings of fullness (also known as satiety) after eating the bread enriched in pulses and conventional white bread.\n\nParticipants will be required:\n\n* To attend for seven study visits over a period of 60 days.\n* Consume a breakfast meal containing either the faba bean-enriched bread or conventional bread over two study periods, each consisting of one 7 hour study visit and two consecutive visits of 2 hours in duration. After 28 days, participants will return for the second study period as above, with a final study visit conducted 28 days later.\n* Give blood samples during 2 x 7 hour study visits\n* Complete visual analogue scales to rate appetite after consuming the faba bean-enriched and conventional white bread.\n* Record dietary intake prior to and during the study period.",[28,282,283],"Cardiometabolic Disease","Low Iron Stores",[285,286,287,288,289,290,291],"faba bean enriched bread","bioavailability","Enrichment of blood haemoglobin with Iron-57 stable isotope","Postprandial Lipaemia","Satiety","Visual analogue scales","Postprandial glycaemia","2024-09-11",{"date":294,"type":39},"2024-09-19",{"date":296,"type":22},"2024-09",{"date":298,"type":22},"2025-09",{"name":300,"class":46},"University of Reading",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":150,"minAge":308,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":4},"100550028","iron-status-in-autism-spectrum-disorders-100550028","NCT06441734","Iron Status in Autism Spectrum Disorders","Iron Status in Autism Spectrum Disorders in Children Attending Assiut Pediatric University Hospital","Inclusion Criteria:\n\n* children who are diagnosed with autism spectrum disorder according to DSM -V\n* not having infection inflammatory conditions chronic physical illness\n* children who are not receiving iron supplementation\n\nExclusion Criteria:\n\n* age below 2 years and above 12 years\n* having an infection or inflammatory conditions chronic physical illness\n* receiving iron supplementation","2 Years","12 Years",{"count":311,"type":22},46,"to evaluate the prevalence of iron deficiency anemia in group with autism spectrum disorders in comparison to normal children group",[28],"2024-07-15",{"date":316,"type":39},"2024-07-16",{"date":318,"type":22},"2024-08-02",{"date":320,"type":22},"2025-07",{"name":322,"class":46},"Assiut University"]